An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II

INTRODUCTION: Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. AIMS: To update the evidence and provide an overview of the available data on icatibant. EVIDENC...

Descripción completa

Detalles Bibliográficos
Autores principales: Floccard, Bernard, Hautin, Etienne, Bouillet, Laurence, Coppere, Brigitte, Allaouchiche, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467996/
https://www.ncbi.nlm.nih.gov/pubmed/23055948
http://dx.doi.org/10.2147/CE.S24743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467996/
https://www.ncbi.nlm.nih.gov/pubmed/23055948
http://dx.doi.org/10.2147/CE.S24743

Ejemplares similares